Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Eur J Clin Pharmacol. 2012 Jul 10;69(3):439–448. doi: 10.1007/s00228-012-1339-x

Fig. 6.

Fig. 6

Simulated effect of clarithromycin on hepatic and intestinal CYP3A activity. A semi-physiologically based pharmacokinetic model incorporating effects of clarithromycin inactivation in the intestine and liver was developed. Clarithromycin 500 mg was administered orally every 12 h. a, b Simulated hepatic and gut-wall concentrations of clarithromycin. c Predicted (line) and observed (box plot/point estimates) hepatic CYP3A activity. d Predicted (line) and observed (box plot/point estimates) gut-wall CYP3A activity